Viewing Study NCT04276493


Ignite Creation Date: 2025-12-25 @ 1:25 AM
Ignite Modification Date: 2026-01-04 @ 6:17 PM
Study NCT ID: NCT04276493
Status: COMPLETED
Last Update Posted: 2024-12-06
First Post: 2020-02-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
Sponsor: BeiGene
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module